Please login to the form below

Not currently logged in
Email:
Password:

durvalumab

This page shows the latest durvalumab news and features for those working in and with pharma, biotech and healthcare.

AZ says target of $45bn sales by 2023 still achievable

AZ says target of $45bn sales by 2023 still achievable

Lynparza (olaparib) for ovarian and breast cancer more than doubled to $438m, while a new lung cancer indication transformed immuno-oncology drug Imfinzi (durvalumab) pushing sales to $371m.

Latest news

More from news
Approximately 10 fully matching, plus 69 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    And AZ’s Imfinzi (durvalumab) meanwhile has shown its worth as a maintenance therapy to stop recurrence of earlier-stage, locally-advanced NSCLC.

  • Pharma deals in August 2015 Pharma deals in August 2015

    AstraZeneca will collaborate with Peregrine on a non-exclusive basis looking at the combination of bavituximab and durvalumab [MEDI4736] in solid tumours. ... No financial terms were disclosed but Mirati will conduct and fund the initial phase I/II

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics